SCHEMBL22566449

SCHEMBL22566449

COc1cc2c(Cc3ccc(NC(=O)C4(C(=O)Nc5ccc(F)cc5)CC4)cc3F)ccnc2cc1OCCCN1CCN(C(=O)OC(C)(C)C)CC1

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MET P08581 19/20 0.63
KDR P35968 8/20 0.63
AXL P30530 7/20 0.63
KIT P10721 5/20 0.63
FLT3 P36888 5/20 0.63
RET P07949 3/20 0.63
PDGFRB P09619 3/20 0.63
MERTK Q12866 3/20 0.63
FLT1 P17948 3/20 0.63
MST1R Q04912 3/20 0.63
AURKA O14965 2/20 0.63
RIPK2 O43353 2/20 0.63
ABL1 P00519 2/20 0.63
EGFR P00533 2/20 0.63
ERBB2 P04626 2/20 0.63
NTRK1 P04629 2/20 0.63
LCK P06239 2/20 0.63
LYN P07948 2/20 0.63
HCK P08631 2/20 0.63
ADRA2A P08913 2/20 0.63

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL371685 0.90 MET (0.79) METKDRAXLKITFLT3
SCHEMBL21982302 0.83 MET (0.80) METKDRAXLKITFLT3
SCHEMBL10254313 0.82 MET (0.63) METKDRAXLKITFLT3
SCHEMBL10321406 0.82 MET (0.66) METKDRAXLKITFLT3
SCHEMBL372180 0.82 MET (0.66) METKDRAXLKITFLT3
SCHEMBL1482799 0.82 MET (0.66) METKDRAXLKITFLT3
SCHEMBL20525847 0.81 MET (0.83) METKDRAXLKITFLT3
SCHEMBL371891 0.81 MET (0.83) METKDRAXLKITFLT3
SCHEMBL19373339 0.80 MET (0.64) METKDRAXLKITFLT3
SCHEMBL29693418 0.80 MET (0.87) METKDRAXLKITFLT3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20200331860-A1 C-Met Modulators and Methods of Use EXELIXIS INC (US) 2020-10-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200331860-A1 C-Met Modulators and Methods of Use FLT4, FLT1, MET MET 3/4885KDR 4/4885AXL 109/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.